<code id='099AA2C337'></code><style id='099AA2C337'></style>
    • <acronym id='099AA2C337'></acronym>
      <center id='099AA2C337'><center id='099AA2C337'><tfoot id='099AA2C337'></tfoot></center><abbr id='099AA2C337'><dir id='099AA2C337'><tfoot id='099AA2C337'></tfoot><noframes id='099AA2C337'>

    • <optgroup id='099AA2C337'><strike id='099AA2C337'><sup id='099AA2C337'></sup></strike><code id='099AA2C337'></code></optgroup>
        1. <b id='099AA2C337'><label id='099AA2C337'><select id='099AA2C337'><dt id='099AA2C337'><span id='099AA2C337'></span></dt></select></label></b><u id='099AA2C337'></u>
          <i id='099AA2C337'><strike id='099AA2C337'><tt id='099AA2C337'><pre id='099AA2C337'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:416
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.
          A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

          AdobeLastweek,theWashingtonPostpublishedanop-edbyformerCDCDirectorTomFriedentitled,“It’stheworld’sle

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          What we’ve learned from the Aduhelm mess

          MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays